June 15, 2020 02:28 PM EDTUpdated June 16, 10:08 AM

The FDA backs off a hasty — and damaging — emergency OK for a potentially dangerous Covid-19 drug

The FDA rushed in with an emergency authorization less than 3 months ago to allow anxious, frightened people the opportunity of using two malaria drugs …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

The FDA backs off a hasty — and damaging — emergency OK for a potentially dangerous Covid-19 drug

This article is available only to Premium subscribers

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

The FDA backs off a hasty — and dam­ag­ing — emer­gency OK for a po­ten­tial­ly dan­ger­ous Covid-19 drug

This article is available only to Premium subscribers

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

The FDA backs off a hasty — and damaging — emergency OK for a potentially dangerous Covid-19 drug

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?